Insertion Mutation in Tnfrsf11a Causes a Paget's Disease-Like Phenotype in Heterozygous Mice and Osteopetrosis in Homozygous Mice.


Journal

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
ISSN: 1523-4681
Titre abrégé: J Bone Miner Res
Pays: United States
ID NLM: 8610640

Informations de publication

Date de publication:
07 2021
Historique:
revised: 06 03 2021
received: 29 03 2020
accepted: 11 03 2021
pubmed: 17 3 2021
medline: 10 8 2021
entrez: 16 3 2021
Statut: ppublish

Résumé

Early onset familial Paget's disease of bone (EoPDB), familial expansile osteolysis, and expansile skeletal hyperphosphatasia are related disorders caused by insertion mutations in exon 1 of the TNFRSF11A gene, which encodes receptor activator of nuclear factor κB (RANK) protein. To understand the mechanisms underlying these disorders, we developed a mouse model carrying the 75dup27 mutation which causes EoPDB. Mice heterozygous for the mutation (Tnfrsf11a

Identifiants

pubmed: 33724536
doi: 10.1002/jbmr.4288
doi:

Substances chimiques

RANK Ligand 0
Receptor Activator of Nuclear Factor-kappa B 0
TNFRSF11A protein, human 0
Tnfrsf11a protein, mouse 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1376-1386

Subventions

Organisme : Medical Research Council
ID : MR/P020941/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0800933/87390
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 060829/Z/00Z
Pays : United Kingdom

Informations de copyright

© 2021 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).

Références

Nakatsuka K, Nishizawa Y, Ralston SH. Phenotypic characterization of early onset Paget's disease of bone caused by a 27-bp duplication in the TNFRSF11A gene. J Bone Miner Res. 2003;18(8):1381-1385.
Riches PL, Imanishi Y, Nakatsuka K, Ralston SH. Clinical and biochemical response of TNFRSF11A-mediated early-onset familial Paget disease to bisphosphonate therapy. Calcif Tissue Int. 2008;83(4):272-275.
Hughes AE, Ralston SH, Marken J, et al. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet. 2000;24(1):45-48.
Ralston SH, Taylor JP. Rare inherited forms of Paget's disease and related syndromes. Calcif Tissue Int. 2019;104(5):501-516.
Crockett JC, Mellis DJ, Shennan KI, et al. Signal peptide mutations in RANK prevent downstream activation of NF-kappaB. J Bone Miner Res. 2011;26(8):1926-1938.
von Heijne G. Signal sequences. The limits of variation. J Mol Biol. 1985;184(1):99-105.
Helfrich MH, Hocking LJ. Genetics and aetiology of Pagetic disorders of bone. Arch Biochem Biophys. 2008;473(2):172-182.
Itzstein C, van't Hof RJ. Osteoclast formation in mouse co-cultures. Methods Mol Biol. 2012;816:177-186.
van't Hof RJ, Dall'Ara E. Analysis of bone architecture in rodents using micro-computed tomography. Methods Mol Biol. 2019;1914:507-531.
Obaid R, Wani SE, Azfer A, et al. Optineurin negatively regulates osteoclast differentiation by modulating NF-kappaB and interferon signaling: implications for Paget's disease. Cell Rep. 2015;13(6):1096-1102.
van't Hof RJ, Rose L, Bassonga E, Daroszewska A. Open source software for semi-automated histomorphometry of bone resorption and formation parameters. Bone. 2017;99:69-79.
Dempster DW, Compston JE, Drezner MK, et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 2013;28(1):2-17.
Daroszewska A, van't Hof RJ, Rojas JA, et al. A point mutation in the ubiquitin-associated domain of SQSMT1 is sufficient to cause a Paget's disease-like disorder in mice. Hum Mol Genet. 2011;20(14):2734-2744.
Daroszewska A, Rose L, Sarsam N, et al. Zoledronic acid prevents pagetic-like lesions and accelerated bone loss in the p62P394L mouse model of Paget's disease. Dis Model Mech. 2018;11(9):dmm035576.
Dougall WC, Glaccum M, Charrier K, et al. RANK is essential for osteoclast and lymph node development. Genes Dev. 1999;13(18):2412-2424.
Boyce BF, Xiu Y, Li J, Xing L, Yao Z. NF-kappaB-mediated regulation of osteoclastogenesis. Endocrinol Metab (Seoul). 2015;30(1):35-44.
Matsumoto M, Sudo T, Saito T, Osada H, Tsujimoto M. Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL). J Biol Chem. 2000;275(40):31155-31161.
Nakamura H, Hirata A, Tsuji T, Yamamoto T. Role of osteoclast extracellular signal-regulated kinase (ERK) in cell survival and maintenance of cell polarity. J Bone Miner Res. 2003;18(7):1198-1205.
Novack DV. Role of NF-kappaB in the skeleton. Cell Res. 2011;21(1):169-182.
Crockett JC, Mellis DJ, Scott DI, Helfrich MH. New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: focus on the RANK/RANKL axis. Osteoporos Int. 2011;22(1):1-20.
Nilsson I, Whitley P, von Heijne G. The COOH-terminal ends of internal signal and signal-anchor sequences are positioned differently in the ER translocase. J Cell Biol. 1994;126(5):1127-1132.
Snapp EL, Hegde RS, Francolini M, et al. Formation of stacked ER cisternae by low affinity protein interactions. J Cell Biol. 2003;163(2):257-269.
Deng J, Lu PD, Zhang Y, et al. Translational repression mediates activation of nuclear factor kappa B by phosphorylated translation initiation factor 2. Mol Cell Biol. 2004;24(23):10161-10168.
Santra M, Dill KA, de Graff AMR. Proteostasis collapse is a driver of cell aging and death. Proc Natl Acad Sci U S A. 2019;116(44):22173-22178.

Auteurs

Nerea Alonso (N)

Rheumatology and Bone Disease Unit, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.

Sachin Wani (S)

Rheumatology and Bone Disease Unit, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.

Lorraine Rose (L)

Rheumatology and Bone Disease Unit, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
Medical Research Council (MRC) Human Genetics Unit, Institute of Genetics and Molecular Medicine (IGMM), University of Edinburgh, Edinburgh, UK.

Rob J Van't Hof (RJ)

Rheumatology and Bone Disease Unit, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
Institute of Aging and Chronic Disease, University of Liverpool, Liverpool, UK.

Stuart H Ralston (SH)

Rheumatology and Bone Disease Unit, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.

Omar M E Albagha (OME)

Rheumatology and Bone Disease Unit, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
College of Health and Life Sciences, Hamad Bin Khalifa University, Doha, Qatar.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH